Synopsis
Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 3-(5-dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid
2. Merrem
3. Penem
4. Ronem
5. Sm 7338
6. Sm-7338
7. Sm7338
1. 96036-03-2
2. Merrem
3. Meropenem Anhydrous
4. Meropenemum
5. Antibiotic Sm 7338
6. Meronem
7. Meropenem [inn]
8. 119478-56-7
9. Mepm
10. Sm 7338
11. Chebi:43968
12. Sm-7338
13. Meropenemum [inn-latin]
14. Merrem I.v.
15. Meropenem (inn)
16. Meropenem, Anhydrous
17. (4r,5s,6s)-3-{[(3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid
18. Meropenem Hydrate
19. Yop6px0bao
20. (4r,5s,6s)-3-[(3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid
21. Ici-194660
22. (4r,5s,6s)-3-{[(3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid
23. Ncgc00016962-01
24. Ici 194660
25. Dsstox_cid_25526
26. Dsstox_rid_80930
27. Dsstox_gsid_45526
28. Ici 194,660
29. Meropenem (as Trihydrate)
30. Meropen
31. (1r,5s,6s)-2-[(3s,5s)-5-dimethylaminocarbonylpyrrolidin-3-ylthio]-6-[(r)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic Acid
32. (4r,5s,6s)-3-(((3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid
33. (4r,5s,6s)-3-[[(3s,5s)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid
34. Meronem (tn)
35. Cas-96036-03-2
36. Nsc-759621
37. Merrem I.v. (tn)
38. Sr-01000762894
39. Unii-yop6px0bao
40. Hsdb 8019
41. Merrem Iv
42. Meropenem,(s)
43. M2279
44. Brn 6940582
45. Meropenem (closed Form)
46. Meropenem [mi]
47. Prestwick0_001106
48. Prestwick1_001106
49. Prestwick2_001106
50. Prestwick3_001106
51. Chembl127
52. Epitope Id:195064
53. Meropenem [who-dd]
54. Schembl34442
55. Bspbio_001212
56. Mls001401437
57. Bidd:gt0851
58. 4-methyl-7-oxo-1-azabicyclo
59. Spbio_003086
60. Bpbio1_001334
61. Meropenem With Sodium Carbonate
62. Dtxsid7045526
63. Gtpl10829
64. Hms1571m14
65. Hms2051g08
66. Hms2090c05
67. Hms2098m14
68. Hms3715m14
69. Meropenem Aslo Known As Meropenemum
70. (4r,5s,6s)-3-[(3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1s)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid
71. 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid, 3-(((3s,5s)-5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-, (4r,5s,6s)-
72. Amy22192
73. Zinc3808779
74. Tox21_110715
75. Tox21_113794
76. Bdbm50129062
77. Mfcd00864966
78. Akos015920140
79. Tox21_110715_1
80. Ccg-100850
81. Cs-1865
82. Db00760
83. Ks-5224
84. Nc00100
85. [3.2.0]hept-2-ene-2-carboxylic Acid
86. Ncgc00179259-01
87. Ncgc00179259-06
88. Ncgc00179259-17
89. Ncgc00253670-01
90. Ncgc00262579-02
91. (6s)-2-{[(3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1r)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic Acid
92. Hy-13678
93. Smr000469184
94. Ab00514051
95. D08185
96. M-2780
97. M05727
98. Ab00514051-02
99. Ab00698370-05
100. Pyrrolidin-3-ylthio)-6-((r)-1-hydroxyethyl)-
101. 036m032
102. Q421670
103. (4r,5s,6s)-3-((3s,5s)-5-(dimethylcarbamoyl)
104. Sr-01000762894-3
105. Sr-01000762894-4
106. Meropenem Trihydrate, Antibiotic For Culture Media Use Only
107. (1r,5s,6s)-2-[(3s,5s)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(r)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic Acid
108. (4r,5s,6s)-3-(((3s,5s)-5-(dimethylcarbamoyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid
109. (4r,5s,6s)-3-(((3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid
110. (4r,5s,6s)-3-((3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid
111. (4r,5s,6s)-3-[[(3s,5s)-5-(dimethylaminocarbonyl)-3-pyrrolidinyl]thio]-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid
112. (4r,6s)-3-((3s,5s)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid
113. 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4r-(3(s*,5s*),4-alpha,5-beta,6-beta(r*)))-
| Molecular Weight | 383.5 g/mol |
|---|---|
| Molecular Formula | C17H25N3O5S |
| XLogP3 | -2.4 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 5 |
| Exact Mass | 383.15149208 g/mol |
| Monoisotopic Mass | 383.15149208 g/mol |
| Topological Polar Surface Area | 136 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 679 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Meropenem |
| PubMed Health | Meropenem (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | Meropenem for Injection, USP (I.V.) is a sterile, pyrogen-free, synthetic, broad-spectrum, carbapenem antibiotic for intravenous administration. It is (4R,5S,6S)-3-[[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-... |
| Active Ingredient | Meropenem |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 500mg/vial; 1gm/vial |
| Market Status | Prescription |
| Company | Hospira; Sandoz; Acs Dobfar |
| 2 of 4 | |
|---|---|
| Drug Name | Merrem |
| PubMed Health | Meropenem (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | MERREM I.V. (meropenem for injection) is a sterile, pyrogen-free, synthetic, broad-spectrum, carbapenem antibiotic for intravenous administration. It is (4R,5S,6S)-3- [[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6- [(1R)-1-hydroxyethyl]-4-m... |
| Active Ingredient | Meropenem |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 500mg/vial; 1gm/vial |
| Market Status | Prescription |
| Company | Astrazeneca |
| 3 of 4 | |
|---|---|
| Drug Name | Meropenem |
| PubMed Health | Meropenem (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | Meropenem for Injection, USP (I.V.) is a sterile, pyrogen-free, synthetic, broad-spectrum, carbapenem antibiotic for intravenous administration. It is (4R,5S,6S)-3-[[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-... |
| Active Ingredient | Meropenem |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 500mg/vial; 1gm/vial |
| Market Status | Prescription |
| Company | Hospira; Sandoz; Acs Dobfar |
| 4 of 4 | |
|---|---|
| Drug Name | Merrem |
| PubMed Health | Meropenem (Injection) |
| Drug Classes | Antibiotic |
| Drug Label | MERREM I.V. (meropenem for injection) is a sterile, pyrogen-free, synthetic, broad-spectrum, carbapenem antibiotic for intravenous administration. It is (4R,5S,6S)-3- [[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6- [(1R)-1-hydroxyethyl]-4-m... |
| Active Ingredient | Meropenem |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 500mg/vial; 1gm/vial |
| Market Status | Prescription |
| Company | Astrazeneca |
Anti-Bacterial Agents
National Library of Medicine's Medical Subject Headings online file (MeSH, 2012)
Meropenem is used for the treatment of intra-abdominal infections, including complicated appendicitis and peritonitis, caused by susceptible bacteria. The drug may be used as monotherapy for the treatment of intra-abdominal infections caused by susceptible viridans streptococci, Escherichia coli, Klebsiella pneumonia, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, or Peptostreptococcus. Because meropenem has a broad spectrum of antibacterial activity, the drug may be used empirically to treat intra-abdominal infections before identification of the causative organism. /Included in US product labeling/
American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 186
Meropenem is used for the treatment of bacterial meningitis caused by susceptible Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), or Neisseria meningitidis in children 3 months of age and older. /Included in US product labeling/
American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 187
The drug also is used in the treatment of meningitis in adults. /NOT included in US product labeling/
American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 187
For more Therapeutic Uses (Complete) data for Meropenem (20 total), please visit the HSDB record page.
Serious and occasionally fatal hypersensitivity reactions (e.g., anaphylaxis) reported with beta-lactams. If hypersensitivity occurs, discontinue meropenem and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, and maintenance of an adequate airway and oxygen).
American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 189
Adverse effects reported in 1% or more of patients receiving meropenem including GI effects (diarrhea, nausea, vomiting, constipation), local reactions (pain and inflammation at injection site, phlebitis/thrombophlebitis), headache, anemia, rash, pruritus, sepsis, apnea, shock, glossitis, and oral candidiasis.
American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 190
Seizures and other adverse CNS effects reported during meropenem therapy, especially in those with underlying CNS disorders (e.g., brain lesions, history of seizures), bacterial meningitis, or compromised renal function. Do not exceed recommended dosage, especially in those with known factors that predispose to seizures. Anticonvulsant therapy should be continued in those with known seizure disorders. If focal tremors, myoclonus, or seizures occur, evaluate the patient neurologically, initiate anticonvulsant therapy if necessary, and determine whether meropenem dosage should be decreased or the drug discontinued.
American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 189
Partial cross-allergenicity among beta-lactam antibiotics, including penicillins, cephalosporins, and other beta-lactams. Prior to initiation of meropenem therapy, make careful inquiry concerning previous hypersensitivity reactions to meropenem, cephalosporins, penicillins, or other drugs.
American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 189
For more Drug Warnings (Complete) data for Meropenem (8 total), please visit the HSDB record page.
For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (excluding vancomycin-resistant isolates), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis and Peptostreptococcus species; complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. Also for use in the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitidis.
FDA Label
Treatment of bacterial sepsis, Treatment of bacterial meningitis
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J01DH02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01D - Other beta-lactam antibacterials
J01DH - Carbapenems
J01DH02 - Meropenem
Route of Elimination
Approximately 70% of the intravenously administered dose is recovered as unchanged meropenem in the urine over 12 hours, after which little further urinary excretion is detectable.
Approximately 70% of the intravenously administered dose is recovered as unchanged meropenem in the urine over 12 hours, after which little further urinary excretion is detectable. Urinary concentrations of meropenem in excess of 10 ug/mL are maintained for up to 5 hours after a 500 mg dose.
US Natl Inst Health; DailyMed. Current Medication Information for MEROPENEM injection, powder, for solution (October 2011). Available from, as of February 8, 2012: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=meropenem
Meropenem is distributed into most body tissues and fluids, including bronchial mucosa, lung, bile, gynecologic tissue (endometrium, myometrium, ovary, cervix, fallopian tube), muscle, heart valves, skin, interstitial and peritoneal fluid, and CSF. Plasma protein binding is approximately 2%. The drug is partially metabolized to at least one microbiologically inactive metabolite. About 70% of an IV dose is eliminated in urine as unchanged drug by tubular secretion and glomerular filtration.
American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 190
At the end of a 30 minute intravenous infusion of a single dose of Meropenem for injection (IV) in healthy volunteers, mean peak plasma concentrations of meropenem are approximately 23 ug/mL (range 14-26) for the 500 mg dose and 49 ug/mL (range 39-58) for the 1 g dose. A 5-minute intravenous bolus injection of Meropenem for injection (IV) in healthy volunteers results in mean peak plasma concentrations of approximately 45 ug/mL (range 18-65) for the 500 mg dose and 112 ug/mL (range 83-140) for the 1 g dose. Following intravenous doses of 500 mg, mean plasma concentrations of meropenem usually decline to approximately 1 ug/mL at 6 hours after administration. No accumulation of meropenem in plasma was observed with regimens using 500 mg administered every 8 hours or 1 g administered every 6 hours in healthy volunteers with normal renal function.
US Natl Inst Health; DailyMed. Current Medication Information for MEROPENEM injection, powder, for solution (October 2011).
Primarily excreted unchanged. There is one metabolite which is microbiologically inactive.
There is one metabolite of meropenem that is microbiologically inactive.
US Natl Inst Health; DailyMed. Current Medication Information for MEROPENEM injection, powder, for solution (October 2011). Available from, as of February 8, 2012: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=meropenem
Approximately 1 hour in adults and children 2 years of age and older with normal renal function. Approximately 1.5 hours in children 3 months to 2 years of age.
The plasma half-life of meropenem is approximately 1 hour in adults with normal renal function and 1.5 hours in children 3 months to 2 years of age. Plasma half-life is increased and clearance of the drug is decreased in patients with renal impairment.
American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 190
The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding- protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus.
The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2, and 4 of Staphylococcus aureus. Bactericidal concentrations (defined as a 3 log10 reduction in cell counts within 12 to 24 hours) are typically 1-2 times the bacteriostatic concentrations of meropenem, with the exception of Listeria monocytogenes, against which lethal activity is not observed.
US Natl Inst Health; DailyMed. Current Medication Information for MEROPENEM injection, powder, for solution (October 2011). Available from, as of February 8, 2012: https://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=meropenem
API SUPPLIERS
Together we can improve the quality of life
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
HRV Pharma - Market Expansion Leader in Pharmaceuticals.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25869
Submission : 2012-03-31
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-10-20
Pay. Date : 2014-07-20
DMF Number : 28279
Submission : 2014-06-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23276
Submission : 2009-11-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29985
Submission : 2016-11-28
Status : Active
Type : II
Date of Issue : 2025-09-24
Valid Till : 2028-07-06
Written Confirmation Number : WC-0378
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25706
Submission : 2011-12-29
Status : Inactive
Type : II
Certificate Number : R0-CEP 2012-089 - Rev 00
Issue Date : 2014-04-07
Type : Chemical
Substance Number : 2234
Status : Withdrawn by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25679
Submission : 2012-01-05
Status : Inactive
Type : II
Certificate Number : R0-CEP 2011-361 - Rev 00
Issue Date : 2014-05-20
Type : Chemical
Substance Number : 2234
Status : Withdrawn by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26538
Submission : 2012-10-08
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Meropenem is a Antibiotic drug, which is currently being evaluated in Phase III clinical studies for the treatment of Pneumonia, Ventilator-Associated.
Lead Product(s): Meropenem,Pralubactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 08, 2026
Lead Product(s) : Meropenem,Pralubactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
Details : Meropenem is a Antibiotic drug, which is currently being evaluated in Phase III clinical studies for the treatment of Pneumonia, Ventilator-Associated.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 08, 2026
Details:
BV100 (Rifabutin) is a Antibiotic drug, which is currently being evaluated in Phase III clinical studies for the treatment of Healthcare-Associated Pneumonia.
Lead Product(s): Rifabutin,Polymyxin B Sulfate,Meropenem
Therapeutic Area: Infections and Infectious Diseases Brand Name: BV100
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 08, 2026
Lead Product(s) : Rifabutin,Polymyxin B Sulfate,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BV100 (Rifabutin) is a Antibiotic drug, which is currently being evaluated in Phase III clinical studies for the treatment of Healthcare-Associated Pneumonia.
Product Name : BV100
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 08, 2026
Details:
Meropenem is a Antibiotic drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Infections.
Lead Product(s): Meropenem,Pralubactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 15, 2025
Lead Product(s) : Meropenem,Pralubactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IV Meropenem-Pralubactam Plasma, Epithelial, Macrophage PK In Healthy Chinese Adults
Details : Meropenem is a Antibiotic drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 15, 2025
Details:
Meropenem is a Antibiotic drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Healthcare-Associated Pneumonia.
Lead Product(s): Meropenem,Pralubactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 28, 2025
Lead Product(s) : Meropenem,Pralubactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Meropenem + Pralurbactam In Carbapenem-Resistant Infections
Details : Meropenem is a Antibiotic drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Healthcare-Associated Pneumonia.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 28, 2025
Details:
ANT3310 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): ANT3310,Meropenem
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Clinartis
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2025
Lead Product(s) : ANT3310,Meropenem
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Clinartis
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants
Details : ANT3310 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2025
Details:
Through the acquisition, Marubeni will leverage the Sumitomo Asian approved products, which includes Meronem (meropenem trihydrate), indicated for Pneumonias.
Lead Product(s): Meropenem,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Meronem
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Marubeni Corporation
Deal Size: $301.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 02, 2025
Lead Product(s) : Meropenem,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Marubeni Corporation
Deal Size : $301.0 million
Deal Type : Acquisition
Marubeni Acquires Sumitomo's Asia Pharma Unit in $480M Deal
Details : Through the acquisition, Marubeni will leverage the Sumitomo Asian approved products, which includes Meronem (meropenem trihydrate), indicated for Pneumonias.
Product Name : Meronem
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 02, 2025
Details:
The agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor.
Lead Product(s): MET-X,Meropenem
Therapeutic Area: Infections and Infectious Diseases Brand Name: MET-X
Study Phase: IND EnablingProduct Type: Antibiotic
Sponsor: Venus Remedies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 27, 2025
Lead Product(s) : MET-X,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Venus Remedies
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Venus Remedies Licenses MET-X from Infex for India Market
Details : The agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor.
Product Name : MET-X
Product Type : Antibiotic
Upfront Cash : Undisclosed
February 27, 2025
Details:
Meropenem is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Meropenem,Vaborbactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2025
Lead Product(s) : Meropenem,Vaborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients Wi...
Details : Meropenem is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 14, 2025
Details:
Meropenem is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pyelonephritis.
Lead Product(s): Meropenem,Vaborbactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibiotic
Sponsor: Biomedical Advanced Research and Development Authority
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 04, 2024
Lead Product(s) : Meropenem,Vaborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Biomedical Advanced Research and Development Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Meropenem is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pyelonephritis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 04, 2024
Details:
Meropenem is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Intraabdominal Infections.
Lead Product(s): Meropenem,Pralubactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 09, 2024
Lead Product(s) : Meropenem,Pralubactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI
Details : Meropenem is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Intraabdominal Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 09, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
Magnesium Mono -P- Nitrobenzyl malonate
CAS Number : 83972-01-4
End Use API : Meropenem
About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...
(2S,4S) -2-(dimethylaminocarbonyl)-4-mercapto- 1- ...
CAS Number : 96034-64-9
End Use API : Meropenem
About The Company : Jiangsu Yutian Pharmaceutical Co., Ltd. is located in Dapu Pharmaceutical Zone of Lianyungang City in Jiangsu Province. It is a new and high-tech enterprise eng...
4-Nitrobenzyl hydrogen malonate
CAS Number : 77359-11-6
End Use API : Meropenem
About The Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs,...
Tert Butyl Dimethyl Silyl Chloride
CAS Number : 18162-48-6
End Use API : Meropenem
About The Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs,...
P-nitrobenzyl(1r,5r,6s)-6-[(1r)-1-hydroxyethyl]-2-...
CAS Number : 90776-59-3
End Use API : Meropenem
About The Company : Zhejiang Jiuzhou Pharmaceutical Co., Ltd. is a medium-scale private enterprise, which focuses in the production of APIs. Our company grows out of Dongshan Chemi...
(R)-4-Nitrobenzyl-2-diazo-4-((2R,3S)-3-((R)-1-hydr...
CAS Number : 137391-68-5
End Use API : Meropenem
About The Company : Zhejiang Jiuzhou Pharmaceutical Co., Ltd. is a medium-scale private enterprise, which focuses in the production of APIs. Our company grows out of Dongshan Chemi...
(2S,4S)-2-[(Dimethylamino)carbonyl]-4-mercapto-1-P...
CAS Number : 96034-64-9
End Use API : Meropenem
About The Company : Zhejiang Jiuzhou Pharmaceutical Co., Ltd. is a medium-scale private enterprise, which focuses in the production of APIs. Our company grows out of Dongshan Chemi...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Together we can improve the quality of life
Regulatory Info :
Registration Country : India
Brand Name : Meropenem
Dosage Form : Sterile Vial
Dosage Strength : 500MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Together we can improve the quality of life
Regulatory Info :
Registration Country : India
Brand Name : Meropenem
Dosage Form : Sterile Vial
Dosage Strength : 1000MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Withdrawn
Registration Country : Malta
Brand Name : Meropenem Zentiva
Dosage Form : Powder For Solution For Injection And Infusion
Dosage Strength : 500MG
Packaging :
Approval Date : 2013-01-07
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Withdrawn
Registration Country : Malta
Brand Name : Meropenem Zentiva
Dosage Form : Powder For Solution For Injection And Infusion
Dosage Strength : 1000MG
Packaging :
Approval Date : 2013-01-07
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : EU Approved
Registration Country : Greece
Brand Name :
Dosage Form : Powder For Solution For Injection or Infusion
Dosage Strength : 500MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Approved
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : EU Approved
Registration Country : Greece
Brand Name :
Dosage Form : Powder For Solution For Injection or Infusion
Dosage Strength : 1GM
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Approved
Registration Country : Greece
Regulatory Info : DISCN
Registration Country : USA
Brand Name : MEROPENEM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 500MG/VIAL
Packaging :
Approval Date : 2010-06-22
Application Number : 90940
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : MEROPENEM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1GM/VIAL
Packaging :
Approval Date : 2010-06-22
Application Number : 90940
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : MERREM IV
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1GM/VIAL
Packaging :
Approval Date : 1996-06-21
Application Number : 50706
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : MERREM IV
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 500MG/VIAL
Packaging :
Approval Date : 1996-06-21
Application Number : 50706
Regulatory Info : DISCN
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - POWDER;INTRAVENOUS - 1GM/VIAL;1GM/VI...DOSAGE - POWDER;INTRAVENOUS - 1GM/VIAL;1GM/VIAL
USFDA APPLICATION NUMBER - 209776
DOSAGE - INJECTABLE;INJECTION - 1GM/VIAL
USFDA APPLICATION NUMBER - 50706
DOSAGE - INJECTABLE;INJECTION - 500MG/VIAL
USFDA APPLICATION NUMBER - 50706
Digital Content
DATA COMPILATION #PharmaFlow
https://www.pharmacompass.com/radio-compass-blog/fda-opoe
NEWS #PharmaBuzz
30 Dec 2025
// PHARMABIZ
01 Dec 2025
// PHARMABIZ
20 Dec 2024
// HEALTH CANADA
22 Jul 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216424
17 Apr 2024
// PHARMABIZ
26 May 2023
// Phalguni Deswal CLINICAL TRIALS ARENA
https://www.clinicaltrialsarena.com/news/antabio-on-quest-to-tackle-antibiotic-resistance/
Global Sales Information
US Medicaid Prescriptions
Company : Amneal Bioscien
Meropenem
Drug Cost (USD) : 246,982
Year : 2023
Prescribers : 785
Prescriptions : 1954
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : App-Premierpro
Meropenem
Drug Cost (USD) : 20,244
Year : 2023
Prescribers : 130
Prescriptions : 248
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Armas Pharmaceu
Meropenem
Drug Cost (USD) : 23,720
Year : 2023
Prescribers : 147
Prescriptions : 310
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Auromedics-Eugi
Meropenem
Drug Cost (USD) : 8,462,679
Year : 2023
Prescribers : 13262
Prescriptions : 38193
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Bluepoint Labor
Meropenem
Drug Cost (USD) : 13,777
Year : 2023
Prescribers : 46
Prescriptions : 92
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Civica, Inc.
Meropenem
Drug Cost (USD) : 12,755
Year : 2023
Prescribers : 36
Prescriptions : 157
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Fresenius Kabi
Meropenem
Drug Cost (USD) : 3,350,025
Year : 2023
Prescribers : 5457
Prescriptions : 15448
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Fresenius-Novap
Meropenem
Drug Cost (USD) : 135,518
Year : 2023
Prescribers : 310
Prescriptions : 929
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Fresenius-Premi
Meropenem
Drug Cost (USD) : 398,270
Year : 2023
Prescribers : 1017
Prescriptions : 2735
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Hosp/Pfiz-Premi
Meropenem
Drug Cost (USD) : 250,977
Year : 2023
Prescribers : 384
Prescriptions : 858
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
APIs
Reply
23 Apr 2025
Reply
29 Jan 2025
Reply
25 Jan 2025
Reply
25 Dec 2024
Reply
05 Sep 2024
Reply
23 Aug 2024
Reply
03 May 2024
Reply
23 Mar 2024
Reply
05 Dec 2023
Reply
04 Aug 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
27
PharmaCompass offers a list of Meropenem API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Meropenem manufacturer or Meropenem supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Meropenem manufacturer or Meropenem supplier.
PharmaCompass also assists you with knowing the Meropenem API Price utilized in the formulation of products. Meropenem API Price is not always fixed or binding as the Meropenem Price is obtained through a variety of data sources. The Meropenem Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Monan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Monan, including repackagers and relabelers. The FDA regulates Monan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Monan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Monan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Monan supplier is an individual or a company that provides Monan active pharmaceutical ingredient (API) or Monan finished formulations upon request. The Monan suppliers may include Monan API manufacturers, exporters, distributors and traders.
click here to find a list of Monan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Monan DMF (Drug Master File) is a document detailing the whole manufacturing process of Monan active pharmaceutical ingredient (API) in detail. Different forms of Monan DMFs exist exist since differing nations have different regulations, such as Monan USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Monan DMF submitted to regulatory agencies in the US is known as a USDMF. Monan USDMF includes data on Monan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Monan USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Monan suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Monan Drug Master File in Japan (Monan JDMF) empowers Monan API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Monan JDMF during the approval evaluation for pharmaceutical products. At the time of Monan JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Monan suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Monan Drug Master File in Korea (Monan KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Monan. The MFDS reviews the Monan KDMF as part of the drug registration process and uses the information provided in the Monan KDMF to evaluate the safety and efficacy of the drug.
After submitting a Monan KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Monan API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Monan suppliers with KDMF on PharmaCompass.
A Monan CEP of the European Pharmacopoeia monograph is often referred to as a Monan Certificate of Suitability (COS). The purpose of a Monan CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Monan EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Monan to their clients by showing that a Monan CEP has been issued for it. The manufacturer submits a Monan CEP (COS) as part of the market authorization procedure, and it takes on the role of a Monan CEP holder for the record. Additionally, the data presented in the Monan CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Monan DMF.
A Monan CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Monan CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Monan suppliers with CEP (COS) on PharmaCompass.
A Monan written confirmation (Monan WC) is an official document issued by a regulatory agency to a Monan manufacturer, verifying that the manufacturing facility of a Monan active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Monan APIs or Monan finished pharmaceutical products to another nation, regulatory agencies frequently require a Monan WC (written confirmation) as part of the regulatory process.
click here to find a list of Monan suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Monan as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Monan API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Monan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Monan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Monan NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Monan suppliers with NDC on PharmaCompass.
Monan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Monan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Monan GMP manufacturer or Monan GMP API supplier for your needs.
A Monan CoA (Certificate of Analysis) is a formal document that attests to Monan's compliance with Monan specifications and serves as a tool for batch-level quality control.
Monan CoA mostly includes findings from lab analyses of a specific batch. For each Monan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Monan may be tested according to a variety of international standards, such as European Pharmacopoeia (Monan EP), Monan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Monan USP).
Share
Comment (5)
